Academic Collaborative Research |
|
| STAR TRACK: STrategic Alliance to initiate paRtnerships in TRAnslational Cardiopulmonary research |
Under the umbrella of the LMU-Cambridge Strategic Partnership, the OTR is coordinating the STAR TRACK project together with the CPC-M bioArchive in Munich. Focusing on cardiopulmonary disease, there are 4 main topics: |
MRC |
|
Developmental Pathway Funding Scheme (DPFS) |
|
| LILACS: Low dose interleukin (IL)-2 in patients with a recent acute coronary syndrome |
A two part project consisting of two randomised controlled clinical trials (LILACS: Phase I/II, randomised, double blind, placebo-controlled, adaptive trial, and IVORY: Phase II, randomised, double-blind, placebo-controlled experimental trial) to test the hypothesis that regulatory Tcells (Tregs) enhanced through supplementation with ld-IL2 will suppress cardiovascular (CV) inflammation, with the aim to ultimately promote tissue repair and limit adverse CV events. The OTR provide project management support to the research team through risk management, regular reporting and liaison with the funder. LILACS: link to recruitment information |
| SINAPPS2: A randomised placebo-controlled trial of immunotherapy in patients with psychosis associated with anti-neuronal membrane antibodies |
A randomised controlled phase II clinical trial to test the hypothesis that immunotherapy is an effective treatment of acute psychosis associated with anti-neuronal membrane antibodies. The OTR liaise closely with the funders, local administrative teams and collaborators in the University of Oxford to ensure smooth project progression. Link to UKRI summary |
| StratosPHere: Stratified adaptive therapeutic studies in pulmonary arterial hypertension (PAH) caused by mutations in BMPR2 |
A two part project consisting of a lab based element to identify specific biomarkers that regulate BMPR2 in PAH, followed by an adaptive, Bayesian-stratified response-adaptive clinical trial, which is aimed at providing a personalised approach to treatment of the disease. The OTR provide project management support to the research team through risk management, regular reporting and liaison with the funder. |
MRC |
|
Experimental Medicine (EM) |
|
| ObiVas: A randomised, double blind, controlled mechanistic study of obinutuzumab versus rituximab in ANCA-associated vasculitis |
The primary aim of this project is to compare the mechanistic effects of two anti-CD20 B-cell depleting agents (Obinutuzumab versus Rituximab) in terms of their ability to 1) deplete tissue B-cells, and 2) attenuate the aberrant T-cell response associated with ANCA-associated vasculitis. This project will take the form of a randomised double-blind controlled trial alongside an extensive biomarker programme. |
MRC/Innovate UK |
|
Expression of Interest: Full Body PET Funding Opportunity |
|
| ANGLIA: An Innovation Network for Total Body PET Research |
The OTR is providing project management support for a bid to host one of two national state-of-the-art centres for the new technology of Total Body PET at the Cambridge Biomedical Campus as part of a national platform for industrial, academic and clinical researchers in the UK. |
EPSRC |
|
Interdisciplinary Research Collaboration (IRC) |
|
| Targeted Delivery for Hard-to-Treat Cancers |
The last 4 decades saw many failed systemic drug repurposing trials and their inability to bypass the Blood-Brain-Barrier to reach brain tumour sites. A biodegradable hydrogel has been developed which offers superior apposition to brain tissue loaded with gemcitabine, for immediate application to the post-resection tumour cavity walls to achieve local cytotoxic effects. The conformal adherence of the hydrogel has a huge potential as a surgical adjunct releasing gemcitabine directly to the margin of the resection targeting remaining GB cells (recurrence happens in 80% of patients). The local rather than systemic delivery profile of hydrogel and the well-known safety profile of gemcitabine, predicts a low toxicity associated with the use of hydrogel. |
National Institute for Health and Care Research (NIHR) |
|
Health Technology Assessment (HTA) |
|
|
OPACE: Optimising azithromycin prevention treatment in COPD to reduce exacerbations (OPACE): A double blind adaptive design pragmatic phase IV randomised controlled trial |
OPACE is a clinical trial investigating the use of Azithromycin for COPD patients. Long-term azithromycin treatment may have benefits but also risks; such as antibiotic resistance and it may be less effective in some patients compared to others. It is therefore important to have evidence to guide the best ways to use azithromycin as a prophylactic agent for patients with COPD. The trial will compare the continuous use of Azithromycin by COPD patients with either seasonal or more permanent cessation use of the antibiotic. The Office for Translational Research helped with the development of the application for funding and are project managing the trial. |
National Institute for Health and Care Research (NIHR) |
|
Invention for Innovation (i4i) |
|
|
NeWTS (Neonatal Wireless Transmission System): Advancing Neonatal Care with Wireless Technology |
Babies in need of hospital care require continuous monitoring of their vital signs, including heart rate, respiratory rate, temperature and oxygen saturation. Currently, this requires placing sensors on a baby that are connected to a patient monitor via multiple wires. These wires tether babies to their cots and makes it difficult for parents to hold their babies and given them comfort (Kangaroo care) which has been shown to improve outcomes for babies and parents. NeWTS is a novel and bespoke wireless bridge between vital sign sensors and the patient monitor. It breaks the barriers that the wires create and allows babies to continue to be monitored during Kangaroo Care. It has the potential to bring about a step change in care for babies requiring intensive care. The OTR provides project management support for NeWTS on the journey form prototype to commercial product. |
NHS Accelerated Access Collaborative |
|
Artificial Intelligence (AI) in Health and Care Award |
|
| OSAIRIS: Open-source AI to augment and accelerate radiotherapy workflows across the NHS |
OSAIRIS uses Microsoft Project InnerEye’s open-source AI toolkit to differentiate tumour and healthy tissue on cancer scans (called ‘segmenting’), prior to radiotherapy treatment with the aim of evaluating how this could save clinicians’ time, reduce the time between the scan and commencing treatment, and scale this out to other NHS Trusts. The OTR provide project management support to the research team through finance management, regular reporting and liaison with the funder. |
Industry Collaborative Research |
|
LifeArc/Addenbrookes Charitable Trust/Kidney Research UK/UNION Therapeutics/GlaxoSmithKline |
|
| PROTECT-V: Prophylaxis for Patients at Risk of Covid-19 Infection |
PROTECT-V is a platform trial to test prophylactic interventions against SARS-CoV2 infection in vulnerable patient populations at particularly high risk of COVID-19 and its complications, seeking to identify treatments that either might prevent the disease from occurring or may reduce the number of cases where the disease becomes serious or life-threatening. Multiple agents can be evaluated on the same platform across multiple vulnerable populations, with the option of adding additional treatments at later time points as these become available. The OTR provide project management support to the research team through finance management, regular reporting and liaison with the funder. |
